Successful pharmacological intervention at different levels of the complement system in an in vitro complement fixation model for bullous pemphigoid

• Published in: Experimental dermatology Vol. 32; no. 5; pp. 632 - 640
• Main Authors: Giang, Jenny, Doorn, Martijn B. A., Diercks, Gilles F. H., Cordoba, Santiago Rodriguez, Bosch, Thierry P. P., Schreurs, Marco W. J., Poppelaars, Felix, Damman, Jeffrey
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.05.2023
• Subjects: Antibodies; Biopsy; Bullous pemphigoid; complement; Complement activation; Complement component C1; Complement component C1q; Complement component C3; Complement component C5; Complement fixation; Complement inhibitors; Complement System Proteins; Dexamethasone; Humans; Immunofluorescence; Immunoglobulins; in vitro; Monoclonal antibodies; Patients; Pemphigoid, Bullous; Properdin; Retrospective Studies; skin; skin; bullous pemphigoid; complement; in vitro; immunofluorescence
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.14755

Bullous pemphigoid (BP) is characterized by deposition of immunoglobulins and complement along the epidermal basement membrane (BM). In humans, there is a lack of functional studies targeting the complement system (CS). This study investigates activation of all complement pathways in BP skin biopsies. Moreover, pharmacological inhibition at different levels of the CS was investigated using anti‐complement compounds in a complement fixation BP assay. In this retrospective study, 21 frozen biopsies from BP patients were stained by direct immunofluorescence for C1q, MBL, ficolin‐2, C4d, properdin, C3c and C5b‐9. Sera from 10 patients were analysed in a complement fixation assay in the presence of C1 inhibitor, anti‐factor B monoclonal antibody (mAb), anti‐C3 mAb and anti‐C5 mAb and compared with dexamethasone. The two readouts were the quantity of complement deposited along the BM and the release of sC5b‐9 in the supernatant. Our results show classical and alternative complement pathway activation in BP skin biopsies, but could not demonstrate significant lectin pathway activation. In contrast to dexamethasone, complement deposition along the BM could be selectively inhibited by anti‐C1 and anti‐ factor B. More downstream, selective intervention at the level of C3 and C5 could effectively reduce complement deposition along the BM and the release of sC5b‐9 in the supernatant. This study shows that selective intervention in either the classical, alternative or terminal pathway prevented deposition of complement along the BM in an in vitro BP model. The results of our study greatly encourage the clinical development of complement inhibitors for the treatment of BP.